Clinical Trials Logo

Plasma Cell Dyscrasia clinical trials

View clinical trials related to Plasma Cell Dyscrasia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02741999 Completed - Clinical trials for Plasma Cell Dyscrasia

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

SAVE
Start date: April 2016
Phase:
Study type: Observational

This protocol seeks to enroll smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significant (MGUS) patients with λ light chain (LC) involvement, a group of patients for whom standard of care is observation not treatment. Patients with SMM and MGUS have a precursor plasma cell disorder from which light chain amyloidosis (AL) can evolve. In this trial, enrolled subjects will have blood and if available bone marrow cells evaluated by molecular testing to determine their clonal λ LC variable region (VL) germline gene. Seventy percent of AL cases involve just 7 germline donors, 5 of which are λ germline donors. The hypothesis that will be tested with this protocol is that the presence of AL germline genes associated with AL in patients with a pre-existing diagnosis of λ SMM or λ MGUS indicates the presence of AL or risk of progression to AL.

NCT ID: NCT02556931 Completed - Multiple Myeloma Clinical Trials

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Start date: December 2015
Phase: Phase 2
Study type: Interventional

To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.

NCT ID: NCT00048412 Completed - Multiple Myeloma Clinical Trials

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

Start date: June 2000
Phase: Phase 1/Phase 2
Study type: Interventional

1. To assess the treatment related mortality of allogeneic stem cell transplantation with non-myeloablative therapy incorporating the lymphodepleting MAb CAMPATH-1H, in patients with hematological diseases and renal cell carcinoma not eligible for conventional (myeloablative) therapy. 2. To assess the time to engraftment and incidence of graft failure in patients receiving this transplant regimen. 3. To assess the safety, pharmacokinetics and immunologic activity of CAMPATH-1H when used as part of a subablative conditioning regimen.